In 2018, Chinese scientist He Jiankui and his team used CRISPR, a gene-editing technology prevalent in biomedical research, to eliminate the CCR5 gene in human twin embryos. This was the first ever clinical trial of such gene alteration in humans, prompted by the team’s desire to render the babies HIV, smallpox, and cholera resistant (Regalado). Despite the team’s favorable intentions, opinions clashed regarding the ethics of CRISPR on human babies and its implications. While utilitarian calculations support the medical use of CRISPR on embryos to reduce potential suffering, an ethical…